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Executive Summary  
It is increasingly recognized that pre-eclampsia has two distinct sub-types, depending on the timing of 
onset: early onset pre-eclampsia, which occurs before 34 weeks of gestation, and late onset pre-
eclampsia, which occurs after 34 weeks. Few studies, however, examine and compare early and late 
onset pre-eclampsia in a low- and middle-income country setting.  
This study’s goal was to establish a profile of patients with hypertensive disorders in pregnancy, 
especially pre-eclampsia and eclampsia, over a two year period. At Kenya’s national referral hospital, 
we examined clinical presentation at admission, management of complications, along with maternal 
and newborn health outcomes in the hospital’s busy maternity unit, to ascertain any differences in 
health outcomes for early and late onset pre-eclampsia. De-identified maternity in-patient records 
were retrospectively reviewed for 620 women who received care for pre-eclampsia (n=429) or 
eclampsia (n=191), along the pregnancy continuum and up to 12 weeks’ postpartum. All eclampsia 
records were included, along with every third pre-eclampsia record, stratified by month and year, for 
the period between September 2015 and October 2017. We recorded, for example, time of diagnosis 
of pre-eclampsia or eclampsia and time of any intervention, such as Caesarean section, to measure 
aspects of care. Maternity unit records, of admission to adult intensive care or newborn intensive care 
units, prolonged hospitalization, and maternal and perinatal or neonatal mortality, were utilized to 
assess the maternal and perinatal outcomes of interest: Specific maternal outcomes include 
eclampsia, dialysis, cerebrovascular accident, and other end organ damage; fetal and neonatal 
outcomes included stillbirth, low birth weight, prematurity, respiratory distress syndrome, necrotizing 
enterocolitis, neonatal jaundice, and convulsions. 
Descriptive statistics and bivariate analyses employed Stata® 13. Statistical tests such as Chi-square 
and t-test tested for associations between women with early versus late onset of pre-eclampsia. 
This study’s findings show that out of the 620 records reviewed, 44 percent (n=273) of pre-eclamptic 
and eclamptic women exhibited early onset of pre-eclampsia, while 56 percent had late onset. Nearly 
one quarter (23%, n=126) of these women were referred from other facilities.  
Women with early onset of pre-eclampsia (compared to late onset) have greater odds of adverse 
maternal and perinatal outcomes including hemolysis elevated liver enzymes and low platelets 
(HELLP) syndrome (OR: 4.34; 1.99-10.19; p<0.001), renal dysfunction (OR; 1.68; 20.71-4.1; 
p<0.001), stillbirth (OR=4.96; 3.10-8.05; p<0.001), and neonatal death (OR: 8.51; 3.82-21.37; 
p<0.001). Neonates born after early onset of pre-eclampsia had increased odds of respiratory 
distress (OR=16.99; 9.02-32.28; p<0.001) and birth asphyxia (OR: 1.89; 0.70-4.79; p<0.142).  
Results also associate early onset of pre-eclampsia with higher odds of prolonged maternal 
hospitalization, beyond seven days (OR=5.76; 3.94-8.42; p<0.001), and antepartum hemorrhage 
(OR=5.80; 1.14 -56.40; p<0.001). 
The profiles and outcomes of women with early onset of pre-eclampsia (compared to late onset) 
suggest that seriousness of morbidity increases with earlier onset. Although not statistically 
significant, more deaths were reported from women presenting with late onset of pre-eclampsia—the 
majority of whom were referred to KNH with eclampsia.  
Early detection, continuous monitoring, identification of risk factors, and prompt referral are critical in 
mitigating the serious consequences of pre-eclampsia and eclampsia. 
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Background 
Globally, about five to 10 percent of women experience hypertensive disorders of pregnancy (HDP)1, 
making it the second leading cause of maternal mortality and morbidity. Most HDP case occur in low- 
and middle-income countries (LMICs)2,3. HDPs include pre-eclampsia and eclampsia, gestational 
hypertension, ‘white coat’ hypertension, chronic hypertension, and chronic hypertension with 
superimposed pre-eclampsia5,6. Pre-eclampsia—hypertension with proteinuria after 20 weeks’ 
pregnancy gestation—complicates about five percent of pregnancies7. Nearly 99 percent of the 
estimated 70,000 to 80,000 annual maternal, and 500,000 annual perinatal, pre-eclampsia-related 
deaths occur in LMICs3,4. 
Pre-eclampsia and eclampsia (PE/E) have a devastating effect on mothers, their fetuses, and 
neonates. Women with PE/E suffer severe morbidity and mortality due to eclampsia, and placental 
abruption, pulmonary edema, acute renal failure, and other organ damages6,8. Infants of mothers with 
pre-eclampsia have approximately twice the risk of neonatal death, and increased risks of low Apgar 
scores, seizures, neonatal encephalopathy, and neonatal intensive care admission6,9. Mothers with 
pre-eclampsia who deliver before 37 weeks of pregnancy are likely to have babies with low birth 
weight10,11. Recent studies in sub-Saharan Africa have identified risk factors for PE/E that include: 
primi-parity and para≥5, low plasma vitamin C, low levels of vitamin D, chronic hypertension, family 
history of hypertension, along with low levels of education12,13. 
Early detection and management of pre-eclampsia is essential. Effective antenatal care (ANC) 
includes early identification of women with pre-eclampsia14, with accelerated visits near and at term, 
in addition to self-referrals by well-informed women, better diagnostic and surveillance capacities, and 
highly specialized care. It also involves follow up and control of chronic and gestational hypertension, 
availability and correct administration of drugs, timely delivery with optimum neonatal care, and 
critical and intensive maternal care15–17. Pre-conception care and good ANC are the mainstays of 
prevention, and in situations where pre-eclampsia or eclampsia (PE/E) are detected early, an 
intensive and multi-disciplinary approach to care is recommended and encouraged18. Adherence to 
stricter treatment protocols for controlling hypertension in pregnancy, including pharmacologic 
therapy for women exhibiting blood pressure of 150/100, has been shown to reduce pregnancy 
risks19. It is also important to emphasise close monitoring of pre-eclampsia in postnatal women, to 
prevent adverse outcomes20.  
Managing pre-eclampsia requires sustained monitoring and care to prevent progression to eclampsia. 
If detected early, clinical management can reduce associated complications. This may apply more to 
early onset pre-eclampsia (EO-PE)21,22.  
The 2014 confidential inquiry into maternal death in Kenya revealed that HDP is the third leading 
cause of maternal mortality, responsible for 20 percent of maternal deaths23. The prevalence of pre-
eclampsia in Kenya is estimated at 5.6 percent to 6.5 percent, based on two 2007 studies at 
Nairobi’s Kenyatta National (KNH) and Aga Khan hospitals24,25. The prevalence of PE/E in rural areas 
may be much higher.  
It is increasingly recognized that pre-eclampsia has two distinct sub-types according to when onset 
occurs: early onset pre-eclampsia (EO-PE), before 34 weeks’ gestation, and late onset pre-eclampsia 
(LO-PE), after 34 weeks. Early onset disease is associated with higher morbidities and worse 
outcomes7,26. Improved maternal and perinatal outcomes, including prematurity, require prompt and 
effective care and, likely, early delivery for women with early onset disease. Pre-term births include all 
live births prior to 37 weeks’ gestation, with extremely pre-term babies prior to 28 weeks, very pre-
term between 28 and 32 weeks, and moderate to late pre-term between 32 and 37 weeks17,27. 
Few evaluations have examined LMIC prevalence or incidence of early versus late onset disease, 
including Kenya, where late presentation and poor management elsewhere may negatively affect 
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outcomes. To better understand and improve care for women experiencing early and late onset PE/E, 
an understanding of the disease burden is required. We therefore examined Kenya’s clinical 
spectrum, including presentation at admission, management of complications, and maternal and 
newborn health (MNH) outcomes at the maternity unit of a national referral hospital.  
Study Goal 
The goal of this study was to determine the profile of PE/E patients, and examine the differences in 
characteristics and health outcomes between EO-PE and LO-PE—for women who received ANC, 
intrapartum care, or postnatal care (PNC) at the national hospital. 
The study hypotheses, linked to the conceptual framework (Figure 1), were: 
 No difference in MNH outcomes for women with EO-PE (<34 weeks) and LO-PE (>=34) 
 No difference in socio-demographic and reproductive health (RH) characteristics of women who 
presented with EO-PE (<<34 weeks) and LO-PE (>=34). 
 No difference in clinical management of women with EO-PE (<<34 weeks) and LO-PE (>=34). 
Figure 1: Conceptual framework1 
 
Methods 
This is a retrospective cohort study design which examined socio-demographic characteristics, 
treatment, outcomes, and fetal and maternal complications among women with EO-PE and LO-PE. It 
draws on a review of de-identified records of women who attended ANC, intrapartum care, and PNC 
services and experienced pre-eclampsia, over a two year period (September 2015 to October 2017).   
                                                     
1  IUGR, Intrauterine growth restriction; SGA, Small-for-Gestational-Age; NRFS, Non-reassuring Fetal Status 
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Study Site 
This study was conducted at Kenyatta National Hospital (KNH), the largest teaching and referral 
hospital in Kenya as well as East Africa. Located approximately three kilometers from Nairobi’s central 
business district, with a capacity of 1,800 beds, KNH serves as a primary hospital for Nairobi County 
residents in addition to referred patients from different parts of Kenya. KNH’s Reproductive Health 
(RH) Department of 220 beds is staffed by consultants, senior house officers, nurses, and midwives, 
and its maternity unit comprises an ANC clinic, labor ward (with 28 beds and 4 delivery couches), two 
maternity theatres (for Caesarean sections and other obstetrics procedures), and ANC (6 beds each) 
and PNC wards (12 beds each).  
The maternity unit’s newborn care unit (NBU) has 60 beds/incubators, and the neonatal intensive 
care unit (NICU) has five incubators/respirators. Sick babies born at KNH, such as those with 
respiratory distress syndrome (RDS), low birth weight (LBW, less than two kilograms (kgs)), and birth 
asphyxia, among other complications, are taken directly to the NBU acute room, then reviewed by a 
neonatologist for NBU or NICU care, according to condition severity. Infants referred to KNH within 24 
hours of birth, either from other facilities or those born before arrival or at home, are reviewed at the 
emergency/causality department and referred directly to NBU, while the mother is admitted to the 
PNC ward. Infants admitted to KNH more than 24 hours after delivery are admitted to the pediatric 
unit, which also have five intensive care unit (ICU) respirators/beds in addition to 60 beds.  
About 100 babies are admitted per day to KNH’s NBU, and stay for an average of 14 days. Healthy 
infants born to mothers with complications such as PE/E are not sent to NBU, with co-rooming 
encouraged if the mother is in a stable condition. If the mother continues to be unwell, relatives are 
advised to take the baby home after 24 hours, when possible. For low weight (2 kg to 2.4 kg) or 
premature babies, kangaroo mother care (KMC) is promoted if the mother‘s condition is stable. 
The ANC clinic sees about 2,164 clients per month, and is staffed by consultants, senior house 
officers, and nurse/midwives. The labor ward operates 24 hours a day and conducts about 1,255 
deliveries per month, and is staffed by a resident, senior house officer, medical officer, clinical officer 
interns, and nurse/midwives. Two daily major ward rounds are conducted by a consultant 
obstetrician/gynecologist (Ob/Gyn) every morning and evening. Pregnant and postnatal women with 
complications, including medical or surgical complications, receive multidisciplinary care either within 
the maternity unit or in other units. Any obstetric case transferred to another unit is managed by 
specialty and obstetric teams; for example, a mother with kidney failure or HELLP syndrome is 
managed by the nephrologist (kidney specialist) and obstetric teams. 
Study Population 
This study population comprises women who received ANC, intrapartum care, or PNC (up to 12 weeks 
following birth) at KNH, or were referred to KNH preceding or following delivery elsewhere; only 
women who delivered at KNH, or delivered elsewhere and were referred to KNH, and suffered from 
PE/E after 20 weeks’ gestation were eligible. Eligibility criteria included PE/E diagnosis with high 
blood pressure, proteinuria, or evidence of end organ damage. Women who had hypertension but not 
PE/E were excluded from the study. 
Sample size and sampling 
A two-proportion sample size calculation, to detect 30 percent difference with 95 percent confidence 
and 80 percent power28, accounting for missing cases, resulted in a sample of 620 women’s records 
for review. The calculation was based on the main outcome: the incidence of adverse events after EO-
PE and LO-PE among pregnant or postnatal women presenting for care at KNH for the indexed 
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pregnancy. Prior studies revealing EO-PE and LO-PE incidence rates of 0.38 percent and 2.7 percent, 
respectively; considering our high risk setting in a referral institution, we used incidence estimates of 
0.4 percent EO-PE and four percent LO-PE to estimate our sample.  
Of 1,529 eligible in-patient records identified, 191 (12.5%) women experienced eclampsia and the 
remainder experienced pre-eclampsia. All eclampsia cases were included since the number was 
small. We then randomly sampled the inpatient records describing pre-eclampsia, stratified by month 
and year of observation resulting to 909 (59.5%). After exclusion of a total of 480 (43.6%) case files 
(due to missing or incomplete data), we achieved a sample of 620 PE/E case files for analysis. Figure 
2 shows the study’s sampling method and record review procedure for the study period.   
Figure 2: Flow diagram of patient’s records sample selection 
 
 
Data Extraction and Analysis 
Two research assistants were trained to extract data from de-identified maternity inpatient records 
focusing on the time of diagnosis of PE/E and the time of any treatment or intervention that enabled 
measurement of clinical management and care. Extractions assessed eligibility (EO-PE or LO-PE) by 
consensus review of the in-patient records and included: medical records, clinician notes or antenatal 
cards for any exposure in the month preceding delivery, gestational age by date, and ultrasound 
results. Data on MNH outcomes were also extracted. Maternal outcomes included eclampsia, 
cerebral vascular accident (CVA), other organ damage, dialysis, prolonged hospitalization admission 
including high dependency or ICU, and mortality. Perinatal outcomes included low birth weight, 
prematurity, respiratory distress syndrome, jaundice, admission to NCU and/or NICU, and mortality,  
Descriptive statistics (frequency and percentage) and measures of central tendency (mean, standard 
deviations, median) are reported. We used chi square, t-test, and calculated odds ratio to determine 
any significant differences between the EO-PE and LO-PE cohorts. Descriptive statistics and bivariate 
analysis compared maternal and neonatal outcomes using Stata® 13. 
Ethical Approval  
This study protocol was approved by Population Council’s research ethics Institutional Review Board, 
as Protocol 813, and the KNH-UoN Ethics and Research Committee, as Protocol 293/06/2017. We 
also received permission to collect data from KNH departments of research and clinical services, 
health information and records, and RH services. 
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Results 
Socio-demographic characteristics 
Of 620 records reviewed, 44 percent (n=273; 45 had eclampsia) exhibited EO-PE, while 56 percent 
(n=34; 74 had eclampsia) had LO-PE. Of the 273 women presenting with EO-PE, 124 (45.4%) were 
less than 30 weeks pregnant, and 149 (54.6%) were between 30 to 33 weeks. For women presenting 
with LO-PE, 39 percent were of 34 to 36 weeks’ gestation, with 61 percent more than 36 weeks. The 
mean gestation age for onset of pre-eclampsia is 29.1 weeks for EO-PE, compared to 37.3 weeks for 
LO-PE. Women with EO-PE were slightly older (mean 29.2, standard deviation (SD) 6.11 years) than 
those with LO-PE (mean 27.8 years, SD 6.34 years; p<0.008). Significantly more women with LO-PE 
delivered by Cesarean section. We were unable to get robust data on the gestation age at ANC 
booking due to missing data (information was not recorded in in-patient records). There were no 
significant differences between the two groups on socio-demographic characteristics of parity, marital 
status, education, work status, and place of residence (Table 1).  
Table 1: Socio-demographic characteristics of study participants 
Characteristics Early Onset (PE) Late Onset (PE) Total P-value 
Age (years) 
 273 SD 347 SD 620 SD  
Mean, SD 29.0 6.1 28.0 6.4 28.0 6.3 0.008 
Parity 
  273 % 347 % 620 % 
0.06 
0 30 11.0 42 12.1 72 11.6 
1 88 32.2 143 41.2 231 37.3 
2 78 28.6 73 21.0 151 24.4 
3+ 77 28.2 89 25.6 166 26.8 
Gravidity 
  273 % 347 % 620 % 
<0.001 
1 72 26.4 150 43.2 222 35.8 
2 80 29.3 83 23.9 163 26.3 
3 66 24.2 59 17.0 125 20.2 
4+ 55 20.1 55 15.9 110 17.7 
Formal Education 
  273 % 347 % 620 % 
0.7 
<= Primary^ 82 30.0 110 31.7 192 31.0 
Secondary 112 41.0 133 38.3 245 39.5 
Tertiary 79 28.9 104 30.0 183 29.5 
Employment 
  273 % 347 % 620 % 
0.5 Employed† 134 49.1 161 46.4 295 47.6 
Unemployed‡ 139 50.9 186 53.6 325 52.4 
Marital Status 
  273 % 347 % 620 % 
0.3 Married  220 80.6 291 83.9 511 82.4 
Single 53 19.4 56 16.1 109 17.6 
Place of Residence 
  273 % 347 % 620 % 
0.01 Nairobi 205 75.1 289 83.3 494 79.7 
Others 68 24.9 58 16.7 126 20.3 
Religion 
 273 % 347 % 620 % 
0.5 Christian 266 97.4 341 98.3 607 97.9 
Muslim 7 2.6 6 1.7 13 2.1 
Mode of delivery 
 242 % 341 % 583 % 
<0.001 Vaginal Delivery** 97 40.0 87 25.5 184 31.6 
Caesarean Section 145 60.0 254 74.5 399 68.4 
12 
GA at onset, weeks 
 273 SD 347 SD 620 SD <0.001 
Mean (SD) 29.2 3.2 37.3 2.1 33.7 4.8 
Significant results (P<0.05) in bold color;  * (n/N*100);  GA - Gestational Age;  ^None and primary education;  † Includes Business, 
self-employed;  ‡ includes housewife;  **includes spontaneous vaginal delivery, assisted delivery and breech delivery 
  
Referrals 
One fifth (20%) of the women with PE/E were referred from outside KNH amounting to a total of 126 
referrals: 20% were referrals from health facilities outside of Nairobi county and 80% from within 
Nairobi county. Most referrals were from Kiambu and Kajiado counties (see Figure 3)—likely due to 
their proximity to Nairobi county. Out of all the referrals into KNH (n=126) there were more women 
with EO-PE (n=68, 54%) than women with LO-PE (n=58, 46%). Figure 3 shows geographically where 
women traveled from to reach KNH in Nairobi (shown as a red dot), with shades of orange indicating 
the counties from which women traveled and the number of women who came from each county. 
Figure 3: Number referred into KNH, by county of residence and distance of referrals  
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Clinical presentation  
The majority of women experienced pre-eclampsia with severe complications, but women with EO-PE 
were more likely to experience pre-eclampsia with severe complications than women with LO-PE (see 
Figure 4). Eclampsia incidence was not associated with occurrence of pre-eclampsia onset.  
Figure 4: PE/E diagnosis 
 
* p <0.001 
Obstetric risk factors  
Figure 5 shows that women with EO-PE were more likely to have chronic hypertension or family history 
of hypertension compared to those with LO-PE. Prior experience of PE was also a major risk factor (1 
in 10) for both EO-PE and LO-PE. Gestational diabetes mellitus and pre-gestational diabetes mellitus 
and prior eclampsia were less common overall (< 2%). 
Figure 5: Obstetric risk factors by pre-eclampsia onset 
1.1
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Pre-eclampsia characteristics 
Table 2 shows the comparison between women with EO-PE and LO-PE based on the severity of their 
disease and blood results. Bivariate analysis show that women with EO-PE were more likely to 
experience severe pre-eclampsia, show highest systolic blood pressure (sBP, i.e. greater than 180 
mmHg), higher diastolic blood pressure (dBP), and lower creatinine than women with LO-PE. There 
were no differences by onset in experience of low haemoglobin and platelet levels (<100000).  
Table 2: Difference between two groups and severity of disease and blood results 
Severity of disease  
and blood results 
EO-PE (n=273) LO-PE (n=347) 
OR [95% CI] p-value 
n (%) n (%) 
Mild Pre-Eclampsia 11 (4.2) 63 (18.1) 0.2 0.1 to 0.4 <0.001 
Severe Pre-Eclampsia 217 (79.3) 210 (60.5) 2.5 1.7 to 3.7 <0.001 
Eclampsia 45 (16.5) 74 (21.5) 0.7 0.5 to 1.1 0.16 
Highest sBP >180 mmHG 128 (46.7) 113 (32.6) 1.9 1.3 to 2.6 <0.001 
Lowest dBP <90 mmHG 67 (24.5) 145 (44.4) 0.4 0.3 to 0.6 <0.001 
Highest SGOT (>70) 77 (28.2) 130 (37.5) 0.7 0.5 to 0.9 0.02 
Highest Creatine (>100) 160 (58.6) 274 (79.9) 0.4 0.3 to 0.5 <0.001 
Lowest HB levels (<10) 18 (6.7) 30 (9.5) 0.7 0.4 to 1.4 0.34 
Lowest Platelets (<100000) 68 (24.9) 110 (31.7) 0.7 0.5 to 1.0 0.06 
    SGOT - serum glutamic-oxaloacetic transaminase;  OR - Odds Ratio;  CI - Confidence Interval 
Pregnancy and fetal outcomes 
Of the 583 women whose delivery information was recorded, 399 (68%) had a Caesarian section (c-
section), of whom 74 (18.5%) had eclampsia. Additionally, 36.3 percent (n=145) of all c-sections were 
among EO-PE women, and 63.7 percent (n=254) were LO-PE (see Table 1). Mean gestational age at 
delivery was lower for EO-PE mothers (30.5 weeks) than LO-PE mothers (37.4 weeks) (p<0.001). 
Live births were more frequent among LO-PE women (91%) than EO-PE women (62%). More stillbirths 
and neonatal deaths occurred among EO-PE women than those with LO-PE (Figure 6). PE/E was 
associated with perinatal/neonatal death (p<0.002), and more neonatal deaths occurred among 
infants of EO-PE mothers (P<0.001) than among LO-PE mothers. No statistically significant difference 
in neonatal deaths was found for EO-PE or LO-PE women (p=0.8) for the three PE/E categories (mild 
pre-eclampsia, severe pre-eclampsia, eclampsia), and there was also no statistically significant 
association between highest sBP and neonatal death (p=0.15) or stillbirth (p=0.8), in both arms. 
Figure 6: Fetal outcomes 
96.1
17.6
35.2
64.8
33.6
2.3
9.4
90.6
0% 20% 40% 60% 80% 100%
Birthweight (<2.5kg)
Neonate Deaths
Still‐birth
Live‐birth
LO‐PE (n = 342) EO‐PE (n =233)
 
15 
Birth weight analysis shows that most babies (63.1%) born to EO-PE mothers weighed from one to two 
kilograms (kgs), while half (50.0%) of those born to LO-PE mothers were between two and three kgs. 
Overall, babies of EO-PE mothers had lower birth weights than those of LO-PE mothers (p<0.001). 
Most pre-term deliveries were moderate to late (>32 to 37 weeks), but more ‘very pre-term’ (28 to 32 
weeks) and ‘extremely pre-term’ (< 28 weeks) deliveries were among EO-PE women (p<0.001). 
Figure 7: Pre-term deliveries among EO-PE and LO-PE women 
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*Fisher’s exact test used when n<5  
Newborn unit and NICU admissions  
A higher proportion of newborns (n=133; 55%) of women with EO-PE were admitted to the NBU 
compared to newborns (n=83; 24%) of women with LO-PE (p<0.001). Only four neonates were 
admitted to NICU (2 per group). Table 4 shows the birthweight of all infants admitted to the NBU. It 
can also be observed that the majority of newborns from women with EO-PE and admitted at the NBU 
had lower birth weight compared to those of women with LO-PE. 
Table 3: Showing birthweight categories of neonates admitted in the Newborn Unit 
Birth weight (kg) 
EO-PE (n=133) LO-PE (n=83) 
Total (n=216) P-value* 
n (%) n (%) 
<=1kg 25 (18.8) 0 (0.0) 25 (11.6) 
0.004 
>1 to 2kg 97 (72.9) 29 (34.9) 126 (58.3) 
>2 to 3kg 8 (6.0) 37 (44.6) 45 (20.8) 
>3 to 4kg 2 (1.5) 12 (14.5) 14 (6.5) 
>4kg 1 (0.8) 5 (6.0) 6 (2.8) 
*Fisher’s exact test used 
Neonatal complications 
Neonatal complications reviewed include asphyxia, respiratory distress syndrome (RDS), neonatal 
jaundice, necrotizing enterocolitis (NEC), neonatal convulsions, and intraventricular haemorrhage 
(IVH). Compared to LO-PE mothers, neonates born of mothers who experienced EO-PE had 
significantly higher chances of having neonatal jaundice, RDS, and requiring breathing support 
through continuous positive airway pressure (CPAP). Birth asphyxia, NEC, and neonatal convulsions 
were also recorded among neonates of mothers with EO-PE (Figure 8, next page). 
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Figure 8: Neonatal complications 
 
* p <0.001; † p<0.01 
Maternal complications 
Women with EO-PE were more likely than those with LO-PE to experience antepartum hemorrhage, 
hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome). In addition, women with 
EO-PE were more likely than those with LO-PE to be admitted for longer durations, due to 
complications. Few women experienced PPH, renal failure, or stroke (less than 6%). Six women died 
(one presenting with EO-PE, and five presenting with LO-PE, Table 4), and all six were admitted at KNH 
in an eclamptic state. Four of the six women who died at KNH arrived in an eclamptic state during the 
early postnatal period. They had attended ANC, and delivered in other health facilities including a 
faith-based hospital, private maternity home, and health centers. Only one (EO-PE) of these deceased 
women was referred from outside Nairobi County. Three of the women who died had received a pre-
referral dose MGSO4. 
Table 4: Maternal complications 
Maternal Complications and Mortality 
EO-PE 
(n=232) 
LO-PE 
(n=341) OR CI 
n (%) n (%) 
Antepartum Hemorrhage-† 8 (3.3) 2 (0.6) 5.80 1.1 to 56.8 
HELLP* 29 (13.0) 10 (3.0) 4.34 2.0 to 10.1 
Postpartum Hemorrhage 9 (3.7) 15 (4.4) 0.84 0.32 to 2.1 
Renal Failure 14 (5.8) 12 (3.5) 1.68 0.71 to 4.1 
Cerebral Vascular Accident (CVA)/Stroke 4 (1.7) 3 (0.9) 1.89 0.32 to 13.0 
Retinal Detachment/Blindness 0 (0.0) 0 (0.0) N/A N/A 
Disseminated Intravascular Coagulation (DIC) 0 (0.0) 2 (0.6) N/A N/A 
Pulmonary Edema 0 (0.0) 1 (0.3) N/A N/A 
Deep Vein Thrombosis 0 (0.0) 2 (0.6) N/A N/A 
Dialysis 8 (3.0) 6 (2.0) 1.90 0.6 to 6.6 
Transfusion 24 (9.9) 23 (6.7) 1.52 0.8 to 2.9 
ICU High Dependency Unit  8 (3.0) 10 (3.0) 1.13 0.4 to 3.2 
Prolonged Hospital Stay > 1 week* 155 (67.0) 81 (24.0) 5.72 3.9 to 8.4 
Death 1 (0.4) 5 (2.0) 0.28 0.01 to 2.5 
Significant results (If CI does not include 1) in bold color;  N/A – not available due to fewer/no cases;  OR - Odds Ratio;   
CI - Confidence Interval. Analysis excludes 37 women discharged at ANC.  
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Management 
Women with EO-PE and LO-PE received treatment with various anti-hypertensive drugs. The most 
widely used medicine for treatment among women with EO-PE and LO-PE was alpha methyldopa 
(aldomet) and nifedipine—given to over 80 percent of women with EO-PE and LO-PE, throughout the 
pregnancy continuum (ANC, labor and delivery, PNC). Use of MgSO4 for managing pre-eclampsia was 
also common during the ANC period (EO-PE 60%, LO-PE 51%). Table 5 charts the use of 
antihypertensive drugs, MgSO4, and other drugs during ANC, labor and delivery, and PNC.  
Table 5: Management of pre-eclampsia and eclampsia 
Drug 
ANC Labor and Delivery* PNC* 
EO-PE 
(n=273) 
LO-PE 
(n=347) 
EO-PE  
(n=242) 
LO-PE 
(n=341) 
EO-PE 
(n=242) 
LO-PE  
(n=341) 
Methyldopa (oral) 94.9 83.3 95.0 84.2 95.0 86.5 
Hydralazine (IV) 25.3 9.5 14.1 5.3 8.7 4.4 
Nifedipine (oral) 94.1 79.5 93.8 81.8 92.2 85.9 
Labetalol (oral) 3.7 1.7 1.7 0.0 1.7 0.0 
MgSO4 60.1 51.3 40.9 39.0 20.3 26.1 
Diazepam 1.1 0.0 0.0 0.6 0.4 0.6 
Phenytoin 1.8 0.3 0.8 0.6 2.1 1.8 
Lasix 3.7 0.9 2.5 1.2 5.4 1.2 
Junior Aspirin 5.5 0.9 0.4 0.0 0.0 0.0 
IV, Intravenous.  *Analysis excludes 37 women discharged at ANC 
 
Few (5.5%) women received aspirin prophylaxis—which is recommended after 12 weeks’ gestation for 
women at high risk of developing pre-eclampsia. Only three percent of women received calcium 
supplements during pregnancy—which are recommended for women with a low calcium diet, to 
prevent complications associated with pre-eclampsia. 
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Discussion 
This study set out to review in-patient records of 620 women who were treated for pre-eclampsia 
(n=429) or eclampsia (n=191) at Kenyatta National Hospital. Patient records were divided into two 
groups: those women who presented with EO-PE and those who presented with LO-PE. There are 
notable distinctions in the clinical presentation and management between EO-PE and LO-PE observed 
in this study, which helps contribute to the reduction of the knowledge gap for this complex maternal 
and fetal medical condition in low-resource settings.  
The two arms differed significantly—for age, gravidity, residence, and delivery modes. Women with EO-
PE were slightly older than those with LO-PE, and more women with LO-PE had a higher gravidity than 
those with EO-PE. Maternal age and gravidity are implicated as pre-eclampsia risk factors29. 
Referrals 
Around one fifth of women diagnosed with PE/E (20%) were referred to KNH from outside Nairobi 
County, most from neighboring counties, although a few traveled from distant locations. Five of the six 
deaths were among women who arrived at KNH in an eclamptic state; four arrived during the early 
postnatal period, after ANC and delivery services elsewhere. Three of the women who died had a pre-
referral dose of MGSO4—although it is unclear when, and the women’s conditions before receiving it. A 
study in Tanzania showed a higher risk of maternal mortality among eclamptic patients when they 
presented in a critically ill or moribund state30. In other studies, most patients received at a referral 
hospital with eclampsia had not received ANC or had received poor management in lower level 
facilities, with poor fetal and maternal outcomes31,32. These results lend credence to the importance 
of early referral for PE/E patients. 
Obstetric risk factors  
Factors such as previous PE/E and chronic hypertension may confer higher risk for EO-PE, as opposed 
to LO-PE. Similar to other studies17,33,34, our study shows that more women who experience LO-PE 
have gestational diabetes and a family history of hypertension, and women with EO-PE have higher 
rates of chronic hypertension.   
Pre-eclampsia risk factors 
Severe pre-eclampsia, high sBP (>180), and high creatinine levels were all associated with EO-PE. 
Almost half of EO-PE women had sBP over 180mmHg, while just over one third of LO-PE women had 
similar blood pressure rates, and the majority in both groups experienced severe pre-eclampsia—but 
more often among EO-PE women, similar to other studies34–37. There was no significant difference 
between the two cohorts of women (EO-PE versus LO-PE) for severity of pre-eclampsia in our study. 
Pregnancy and fetal outcomes 
A high proportion of pregnancies (more than two thirds) resulted in c-section—with significantly more 
among women with LO-PE (75%) than with EO-PE (60%). Evidence from other studies comparing 
outcomes for infants born to EO-PE women, through vaginal or c-section delivery, is weak38. 
Obstetricians usually face challenges in determining optimal mode of delivery for PE/E patients 
because there is no difference in delivery outcomes39,40. Our study shows no significant difference in 
outcomes between infants born via c-section or by spontaneous vaginal delivery. 
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Neonatal outcomes and complications 
The data also show that women with EO-PE were more likely to have poor fetal outcomes, resulting in 
stillbirth, low birth weight, premature birth, or infants with complications. Babies born to EO-PE women 
were more likely to experience respiratory distress syndrome, necrotizing enterocolitis, and neonatal 
jaundice than those whose mothers had LO-PE. This resonates with other research finding impaired 
neonatal growth along with higher perinatal mortality and morbidity among EO-PE mothers than 
among non-PE as well as LO-PE women35,41,42. 
NICU/NBU admission 
There is a significant difference in NBU admission between infants born to EO-PE mothers and those 
of LO-PE mothers. A surprising proportion of heavier babies also experienced neonatal convulsions 
and were admitted to the NBU. Because KNH is a national referral hospital for the most complex 
cases, there is a relatively high proportion NICU infants, regardless of PE/E onset. This study aligns 
with a number of others showing higher rates of neonatal deaths, premature births, NICU admission, 
and severe neonatal morbidity for infants born to mothers with EO-PE43–45.  
Maternal complications 
More EO-PE women experienced HELLP syndrome and antepartum hemorrhage than LO-PE women. 
Sub-optimal management, particularly at earlier stages of pregnancy, can lead to death, as seen in 
this study’s small sample of women who died. A health system approach, focused particularly on 
skilled provider availability, specifically midwives, with training in emergency obstetric and neonatal 
care (EmONC), in addition to facility preparedness for measuring blood pressure, effective blood 
pressure management, and close follow up throughout pregnancy, with timely referrals, can 
contribute to reductions in maternal (and newborn) deaths46–49.   
Discontinuity in HDP management often occurs in the postnatal period, highlighting the need to build 
on studies reporting incidences of postnatal hypertension27,50. Satisfactory PNC includes careful 
clinical evaluation of blood pressure, among other postnatal vital signs, during the hospital stay, with 
delayed discharge if hypertension continues, in addition to women’s awareness of danger signs, such 
as headache and dizziness, after they return home51,52.  
Treatment 
Early detection of pre-eclampsia is crucial to ensure patients start appropriate management, which 
includes providing information on dangers signs and follow up care22,53. This study shows similar use 
of antihypertensives and MgSO4 among the two cohorts (e.g. EO-PE and LO-PE). Although we are 
unable to demonstrate whether the timing of these drugs had any effect on maternal and fetal 
outcomes, judicial use of antihypertensives for moderate to severe HDP can reduce PE/E 
complications during the antenatal and postnatal periods9,17,27,49,54. 
Limitations 
Our study was limited by its retrospective nature, and our findings need to be interpreted with caution. 
In certain cases, onset of pre-eclampsia may have occurred a few days before hospital referral or 
admission. The lag between onset of PE and diagnosis during referral or admission may have resulted 
in misclassifying some EO-PE as LO-PE. 
Due to poor routine record-keeping (e.g. scant information on referral and clinical forms), we were 
unable to collect critical data that would have helped assess more of the clinical management 
aspects of referred patients, particularly drug dosages, their administration routes, and treatment. 
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This information would have allowed better understanding of which women who were treated received 
a pre-referral loading dose of MgSO4, as well as other treatment or clinical management, and their 
effects on fetal and maternal outcomes.  
It was also difficult to retrieve and match newborn files to those of their mothers due to the filing 
systems, which delaying data collection.  
It would have been helpful to collect information on the proportions of EO-PE and LO-PE women who 
came to KNH with a live baby and those who had a stillbirth before arriving, to also understand 
variations and effects of pre-eclampsia management across the pregnancy continuum.  
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Conclusion  
Early onset of pre-eclampsia is associated with greater disease severity as well as adverse maternal 
and perinatal outcomes, but eclampsia during the postnatal period is more likely to have devastating 
maternal outcomes. It is critical to closely monitor women for danger signs, both at facilities and at 
their homes, throughout the pregnancy continuum. Relevant interventions during ANC and PNC 
contacts with mothers, such as screening and history-taking, blood pressure measurement, and 
effective use of antihypertensive, must be prioritized, which will effectively reduce poor maternal and 
newborn outcomes. There is an added need to improve provider awareness and capacities for 
detecting pre-eclampsia early in pregnancy, which may mitigate adverse outcomes.  
These results recommend the need for a Hypertensive Disorders of Pregnancy Registry that will store 
the medical information of women diagnosed with HDP, with their family histories. It can serve as a 
resource for prospective observational and interventional studies at KNH, in Kenya in general, and 
elsewhere, that will lead to improved prediction of the risk of PE/E, and help establish new treatment 
regimens. As the leading referral hospital in Kenya, KNH wants to develop an HDP response team, for 
better management of future clients as well as informing the national guidelines. 
This study’s results disclose that EO-PE ultimately had greater adverse effects on newborns than on 
LO-PE women. This outcome reveals pre-eclampsia’s heterogeneous nature and that its onset is a 
crucial indicator for the disease’s severity. 
Key Messages 
Early Detection: Both ANC and PNC are critical platforms for pre-eclampsia detection. 
Provider and community awareness of PE/E danger signs and information,  
with access to functional blood pressure-measuring equipment, may enhance  
early identification. 
Identifying Risk Factors: This study shows that chronic high blood pressure and family 
history of pre-eclampsia are important risk factors for pre-eclampsia. Providers’,  
as well as pregnant women’s and community members’, knowledge of PE/E risk 
factors are important for its prevention and management.     
Continuous Monitoring: Once pre-eclampsia is identified, it is important to monitor 
the woman continuously to avert the disease’s serious fetal and maternal 
consequences, and progression to eclampsia. 
Focus on PNC: Many deaths analyzed in the study were due to eclampsia identified 
during the PNC period, suggesting failure to identify pre-eclampsia during ANC or early 
PNC. In addition to prompt detection of PE/E, effective PNC is critical in managing 
immediate PE/E complications and well as counselling on PE/E’s long-term 
consequences for both mother and baby  
Record-keeping: In this study, records especially referral and clinical management notes  
of PE/E were inadequately kept. While this is not peculiar for this study, adequate record 
keeping is essential for continuity of care and future references informing management, 
programs, and policy.  
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Appendix 
Study operational definitions 
High blood pressure (BP) during pregnancy: BP of 140/90 mmHg or more measured on two 
consecutive times in a relaxed client, four hours apart, or a systolic BP measurement ≥160mmHg or a 
diastolic BP measurement after one measurement in a relaxed client. 
Mild hypertension: Systolic BP 140 to 149 mmHg and or diastolic BP 90 to 109 mmHg 
Severe hypertension: Systolic BP ≥ 160mmHg and/or diastolic BP ≥110mmHg 
Chronic hypertension in pregnancy: Pre-existing hypertension, that predates the pregnancy.  
Gestational hypertension: High BP with first onset after 20th week of pregnancy (second half of 
pregnancy) without associated significant proteinuria.  
Pre-eclampsia: High BP (140/90 mmHg or higher) associated with significant proteinuria occurring for 
first time after second half of pregnancy (after 20 weeks’ gestation) in a previously normal individual. 
Women with pregnancy-induced high BP, with albumin in urine, are defined as pre-eclamptic. 
Severe pre-eclampsia: Severe pre-eclampsia is pre-eclampsia with severe hypertension and/or with 
symptoms, and/or biochemical and/or hematological impairment (NICE 2010). 
a) Diastolic BP ≥110 mmHg or systolic ≥160mmHg after two measurements, four hours apart, with 
albumin in urine; or 
b) Diastolic BP is 90 to 109 mmHg or systolic ≥160mmHg after two measurements, four hours 
apart, with albumin in urine and severe headache, and/or blurred vision, and/or pain in upper 
abdomen. This is now known as pre-eclampsia with severe features. 
Eclampsia: Pregnancy-induced high BP (140/90 mmHg or greater), excess protein in urine and 
occurrence of generalized convulsions/seizures during pregnancy, labor or within 42 days of delivery 
in the absence of epilepsy or another condition predisposing to convulsions (Sibai BM, 2005) 
Eclampsia occurs: 38% to 55% during pregnancy 
 13% to 36% intrapartum  
 5% to 39% within 48 hours of giving birth  
 5% to 17% greater than 48 hours after birth.      
Cerebrovascular accident (CVA) or stroke: Hemiparesis and/or blindness developed during pregnancy 
or in the 42 days postpartum lasting greater than 48 hours. CVA/Stroke implies sudden cessation of 
blood flow to brain cells either as a result of rupture or blockage of the supplying blood vessels 
leading to temporary or permanent loss of motor function, speech impairment, loss of memory and 
occasionally coma (prolonged unconsciousness for 12 or more hours) or death. 
